What We're Reading: Page 66
Industry reads hand-picked by our editors
Jan 03, 2024
-
MIT Technology Review
We’ve never understood how hunger works. That might be about to change.
-
Reuters
Agios Pharma’s blood disorder drug meets goals of late-stage study
-
Science
Giant project will chart human immune diversity to improve drugs and vaccines
-
Bloomberg Law
FTC Gets Court Backing to Halt IQVIA’s Purchase of Propel Media
Jan 02, 2024
Dec 22, 2023
-
ApexOnco
A new order in BTK inhibition
-
Reuters
Jazz Pharmaceuticals’ PTSD drug fails in mid-stage trial
-
The Wall Street Journal
Ultragenyx to Pay $6 Million to Settle Alleged False Medicare, Medicaid Claims
-
Fierce Biotech
AlloVir’s shares plunge 64% in wake of triple phase 3 disaster
Dec 21, 2023
-
The Philadelphia Inquirer
Merck’s diabetes drug highlights debate over U.S. patent system
-
Stat
Advocates call out ‘SNL’ over stereotypes, errors in sickle cell skit
-
BioSpace
Merck’s Chronic Cough Drug Fails to Secure FDA Approval for Second Time
-
The Wall Street Journal
Startup Fauna Bio Studies Animal Genomes for Clues to Human Diseases
Dec 20, 2023
Dec 19, 2023
-
The New York Times
Behind the Shortage Keeping Cancer Patients From Chemo
-
Axios
Weight-loss drugs now being paired with bariatric surgery
-
Financial Times
FT Person of the Year: Lars Fruergaard Jørgensen of Novo Nordisk
-
The New Yorker
All The Carcinogens We Cannot See
Previous
